4-溴苯基锂 | 22480-64-4

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 中文名称: 4-溴苯基锂
• 英文名称: 4-bromophenyllithium
• 英文别名: p-bromophenyllithium
• CAS: 22480-64-4
• 化学式: C₆H₄BrLi
• 分子量: 162.943
• InChiKey: KYCJGUYSNMURAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.81
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-溴苯基锂 在 Li 作用下， 以 乙醚 为溶剂， 生成 1,4-bis(trimethylstannyl)benzene
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Sn: Org.Verb.2, 1.1.2.1.11.3, page 131 - 139

  摘要：

  DOI：
• 作为产物：
  描述：

  1,4-二溴苯 在 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 1.0h， 生成 4-溴苯基锂
  参考文献：
  名称：

  NOVEL COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE ELEMENT, ORGANIC ELECTROLUMINESCENCE ELEMENT, AND ELECTRONIC DEVICE

  摘要：

  公开号：

  EP2896621B1

文献信息

• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAMIDE SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011076678A1

  公开（公告）日：2011-06-30

  The invention relates to compounds of formula I wherein R is hydrogen or lower alkyl; R1 is -(CH2)n-(O)o-heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydroxy, halogen or by -(CH2)p-aryl; n is 0, 1 or 2; o is 0 or 1; p is 0, 1 or 2; R2 is CF3, cycloalkyl, optionally substituted by lower alkoxy or halogen, or is indan-2-yl, or is heterocycloalkyl, optionally substituted by heteroaryl, or is aryl or heteroaryl, wherein the aromatic rings are optionally substituted by one or two substituents, selected from lower alkyl, halogen, heteroaryl, hydroxy, CF3, OCF3, OCH2CF3, OCH2-cycloalkyl, OCH2C(CH2OH)(CH2C1)(CH3), S-lower alkyl, lower alkoxy, CH2-lower alkoxy, lower alkinyl or cyano, or by-C(O)-phenyl, -O-phenyl, -O- CH2-phenyl, phenyl or -CH2-phenyl, and wherein the phenyl rings may optionally be substituted by halogen, -C(O)-lower alkyl, -C(O)OH or -C(O)O-lower alkyl, or the aromatic rings are optionally substituted by heterocycloalkyl, OCH2-oxetan-3-yl or O-tetrahydropyran-4-yl, optionally substituted by lower alkyl; X is a bond, -NR'-, -CH2NH-, -CHR''-, -(CHR'')q-O-, -O-(CHR'')q- or -(CH2)2-; Y is a bond or -CH2- R' is hydrogen or lower alkyl, R'' is hydrogen, lower alkyl, CF3, lower alkoxy, q is 0, 1, 2 or 3; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式I的化合物，其中R是氢或较低的烷基；R1是-(CH2)n-(O)o-杂环烷基或-C(O)-杂环烷基，其中杂环烷基基团可选择地被较低的烷基，羟基，卤素或-(CH2)p-芳基取代；n为0、1或2；o为0或1；p为0、1或2；R2为CF3，环烷基，可选择地被较低的烷氧基或卤素取代，或为茚-2-基，或为杂环烷基，可选择地被杂芳基取代，或为芳基或杂芳基，其中芳香环可选择地被来自较低的烷基，卤素，杂芳基，羟基，CF3，OCF3，OCH2CF3，OCH2-环烷基，OCH2C(CH2OH)(CH2C1)(CH3)，S-较低的烷基，较低的烷氧基，CH2-较低的烷氧基，较低的炔基或氰基，或-C(O)-苯基，-O-苯基，-O-CH2-苯基，苯基或-CH2-苯基选择的一个或两个取代基取代，其中苯环可选择地被卤素，-C(O)-较低的烷基，-C(O)OH或-C(O)O-较低的烷基取代，或芳香环可选择地被杂环烷基，OCH2-氧杂环戊烷-3-基或O-四氢吡喃-4-基，可选择地被较低的烷基取代；X为键，-NR'-，-CH2NH-，-CHR''-，-(CHR'')q-O-，-O-(CHR'')q-或-(CH2)2-；Y为键或-CH2-；R'为氢或较低的烷基，R''为氢，较低的烷基，CF3，较低的烷氧基，q为0、1、2或3；或其药学上适宜的酸盐。现已发现，该式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对于TAAR1。这些化合物可用于治疗抑郁症，焦虑症，躁郁症，注意力缺陷多动障碍（ADHD），与压力有关的疾病，如精神分裂症，帕金森病等神经疾病，阿尔茨海默病等神经退行性疾病，癫痫，偏头痛，高血压，物质滥用和代谢性疾病，如进食障碍，糖尿病，糖尿病并发症，肥胖症，血脂异常，能量消耗和吸收异常，体温稳态异常，睡眠和昼夜节律异常，以及心血管疾病。
• DONOR-ACCEPTOR NANOHOOP COMPOUNDS AND METHODS OF MAKING AND USING THE SAME
  申请人：University of Oregon

  公开号：US20160372684A1

  公开（公告）日：2016-12-22

  Disclosed herein are embodiments of nanostructure compounds that exhibit unique shape configurations, such as nanohoops. The compounds disclosed herein exhibit unique chemical and electrochemical properties that can be tuned and modified to facilitate their use in a variety of different applications.

  本文披露了一些纳米结构化合物的实施例，这些化合物具有独特的形状配置，如纳米环。本文披露的化合物具有独特的化学和电化学性质，可以进行调节和修改，以促进它们在各种不同应用中的使用。
• Enantioselective Conia-Ene-Type Cyclizations of Alkynyl Ketones through Cooperative Action of B(C₆F₅)₃, <i>N</i>-Alkylamine and a Zn-Based Catalyst
  作者：Min Cao、Ahmet Yesilcimen、Masayuki Wasa

  DOI：10.1021/jacs.8b13757

  日期：2019.3.13

  An efficient and highly enantioselective Conia-ene-type process has been developed. Reactions are catalyzed by a combination of B(C6F5)3, an N-alkylamine and a BOX-ZnI2 complex. Specifically, through cooperative action of B(C6F5)3 and amine, ketones with poorly acidic α-C-H bonds can be converted in situ to the corresponding enolates. Subsequent enantioselective cyclization involving a BOX-ZnI2-activated

  已开发出一种高效且高度对映选择性的 Conia-ene 型工艺。反应由 B(C6F5)3、N-烷基胺和 BOX-ZnI2 复合物的组合催化。具体而言，通过 B(C6F5)3 和胺的协同作用，具有弱酸性 α-CH 键的酮可以原位转化为相应的烯醇化物。随后涉及 BOX-ZnI2 活化炔烃的对映选择性环化导致各种环戊烯的形成，产率高达 99% 和 99:1。
• SUBSTITUTED BENZAMIDES
  申请人：Groebke Zbinden Katrin

  公开号：US20110152245A1

  公开（公告）日：2011-06-23

  The invention relates to compounds of formula wherein R, R 1 , R 2 , X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  该发明涉及以下式的化合物 其中R、R1、R2、X和Y如本文所定义，并且其药学上适宜的酸盐。 式I的化合物对痕量胺相关受体（TAARs）具有良好的亲和力，特别是对TAAR1。这些化合物可用于治疗抑郁症、焦虑障碍、双相情感障碍、注意缺陷多动障碍（ADHD）、与压力有关的障碍、如精神分裂症的精神障碍、如帕金森病的神经疾病、如阿尔茨海默病的神经退行性疾病、癫痫、偏头痛、高血压、物质滥用和代谢性障碍，如进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍、睡眠和昼夜节律障碍，以及心血管疾病。
• SNAr reactions of β-substituted porphyrins and the synthesis of meso substituted tetrabenzoporphyrins
  作者：Mathias O. Senge、Ines Bischoff

  DOI：10.1016/j.tetlet.2003.12.121

  日期：2004.2

  suitable for further transformations with residues such as –p-C6H5Br, –p-C6H5–CCH, –p-C6H5–NH2 or –(CH2)3–CHCH2. Similar reactions of tetrabenzoporphyrin with alkyllithium reagents afforded the first entry into meso mono- and dialkylsubstituted tetrabenzoporphyrins while reaction of bicyclo[2.2.2]oct-type masked isoindole precursors with LiR followed by in situ retro-Diels–Alder reaction also afforded

  - 2,3,7,8,12,13,17,18-八乙基卟啉与含有官能团的容易产率中位取代的适合于与残基如进一步转化衍生物LIR试剂的反应p -C 6 H ^ 5 BR， - p - C 6 H 5 –CCH，– p -C 6 H 5 –NH 2或–（CH 2）3 –CHCH 2。四苯并卟啉与烷基锂试剂的类似反应提供了首先进入内消旋的单和二烷基取代的四苯并卟啉，而双环[2.2.2]八型掩蔽的异吲哚前体与LiR的反应，然后原位逆Diels-Alder反应也提供了5-高纯度的苯基和5,10-二苯基四苯并卟啉。